The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. INmune Bio Inc’s current trading price is -74.05% away from its 52-week high, while its distance from the 52-week low is 59.79%. The stock’s price range for this period has been between $1.89 and $11.64 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 5.39 million for the day, a number notably higher than the average daily volume of 2.74 million over the last three months.
INmune Bio Inc (INMB) stock is currently valued at $3.02. During the last session, the stock experienced a remarkable rise, reaching $30.0 after opening at $3.02. The stock briefly dropped to $0.6 before ultimately closing at $2.71.
INmune Bio Inc ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $11.64 on 06/27/25, while the lowest value for the same period was recorded at $1.89 on 07/01/25.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
INmune Bio Inc (INMB) has experienced a quarterly decline of -61.38% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 80.29M and boasts a workforce of 22 employees.
INmune Bio Inc: What Analysts Are Saying
As of right now, 2 analysts are rating INmune Bio Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts are recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 6.53, with a change in price of -5.02. Similarly, INmune Bio Inc recorded 1,848,176 in trading volume during the last 100 days, posting a change of -61.97%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for INMB stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.
INMB Stock Stochastic Average
As of today, INmune Bio Inc’s raw stochastic average for the last 50 days stands at 12.21%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 87.90%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 35.14% and 17.47%, respectively.
INMB Stock Price Performance Analysis
Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. Until today this year the stock’s price performance recorded a decrease of -63.44%. However, over the last six months, the performance has been stronger by -64.30%. The price of INMB decreased -51.91% over the last 30 days. And in the last five days, it has surged by 26.89%.
